Skip to main content
Top
Published in: Translational Neurodegeneration 1/2024

Open Access 01-12-2024 | Research

Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey

Authors: Pei Huang, Yu-Yan Tan, Biao Chen, Hui-Fang Shang, Li-Juan Wang, Chun-Feng Liu, Ling Chen, Ying Chang, Han Wang, Xue-Lian Wang, Xiao-Guang Lei, Li-Fen Yao, Yang Yu, Zheng Ye, Hai-Bo Chen, Sheng-Di Chen

Published in: Translational Neurodegeneration | Issue 1/2024

Login to get access

Abstract

Background

Little is known about the impact of the COVID-19 pandemic on patients with Parkinson’s disease (PD) at different stages of the pandemic. This study aims to assess the lives and disease status of PD patients during the zero-COVID policy period and after ending the zero-COVID policy.

Methods

This multicenter cross-sectional study included two online surveys among PD patients in China, from May 30 to June 30 in 2022 and from January 1 to February 28 in 2023, respectively. The survey questionnaires contained four sections: (1) status of COVID-19 infection; (2) impact on motor and non-motor symptoms; (3) impact on daily and social lives; and (4) impact on PD disease management.

Results

A total of 1764 PD patients participated in the first online survey, with 200 patients having lockdown experience and 3 being COVID-19-positive (0.17%). In addition, 537 patients participated in the second online survey, with 467 patients having COVID-19 infection (86.96%). (1) During zero-COVID, all of the COVID-19-positive patients had mild symptoms of COVID-19 and no death was reported. After zero-COVID, 83.51% of the COVID-19-positive patients had mild symptoms. The overall death rate and inpatient mortality rate of COVID-19-positive PD patients were 3.21% and 30.00%, respectively. (2) During zero-COVID, 49.43% of PD patients reported worsening of PD-related symptoms (lockdown vs. unlockdown, 60.50% vs. 48.02%, P = 0.0009). After zero-COVID, 54.93% of PD patients reported worsening of PD-related symptoms (COVID-19 positive vs. COVID-19 negative, 59.31% vs. 25.71%, P < 0.0001). (3) During zero-COVID, 62.36% of patients felt worried, and ‘limited outdoor activities’ (55.39%) was the top reason for mental health problems. After zero-COVID, 59.03% of patients felt worried, with ‘poor health’ (58.10%) being the top reason. The PD patients tended to change their daily activities from offline to online, and their economic and caregiver burdens increased both during and after zero-COVID. (4) Most PD patients would like to choose online rehabilitation during (69.56%) and after zero-COVID (69.27%). The demand for online medication purchasing also increased during (47.00%) and after zero-COVID (26.63%).

Conclusions

The COVID-19 pandemic aggravated the motor and non-motor symptoms of PD patients either during or after the zero-COVID policy period. The PD patients also experienced prominent mental health problems, changes in daily activities, and increases in economic and caregiver burdens. The COVID-19 pandemic has changed ways of PD management with increasing demands for online medication purchasing and rehabilitation.
Appendix
Available only for authorised users
Literature
1.
5.
go back to reference Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, et al. The effect of the COVID-19 pandemic on people with Parkinson’s disease. J Parkinsons Dis. 2020;10(4):1365–77.CrossRefPubMedPubMedCentral Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, et al. The effect of the COVID-19 pandemic on people with Parkinson’s disease. J Parkinsons Dis. 2020;10(4):1365–77.CrossRefPubMedPubMedCentral
6.
go back to reference Scherbaum R, Kwon EH, Richter D, Bartig D, Gold R, Krogias C, et al. Clinical profiles and mortality of COVID-19 inpatients with Parkinson’s disease in Germany. Mov Disord. 2021;36(5):1049–57.CrossRefPubMedPubMedCentral Scherbaum R, Kwon EH, Richter D, Bartig D, Gold R, Krogias C, et al. Clinical profiles and mortality of COVID-19 inpatients with Parkinson’s disease in Germany. Mov Disord. 2021;36(5):1049–57.CrossRefPubMedPubMedCentral
7.
go back to reference Vignatelli L, Zenesini C, Belotti LMB, Baldin E, Bonavina G, Calandra-Buonaura G, et al. Risk of hospitalization and death for COVID-19 in people with Parkinson’s disease or Parkinsonism. Mov Disord. 2021;36(1):1–10.CrossRefPubMed Vignatelli L, Zenesini C, Belotti LMB, Baldin E, Bonavina G, Calandra-Buonaura G, et al. Risk of hospitalization and death for COVID-19 in people with Parkinson’s disease or Parkinsonism. Mov Disord. 2021;36(1):1–10.CrossRefPubMed
8.
go back to reference Huang P, Zhang LY, Tan YY, Chen SD. Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms. Transl Neurodegener. 2023;12(1):5.CrossRefPubMedPubMedCentral Huang P, Zhang LY, Tan YY, Chen SD. Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms. Transl Neurodegener. 2023;12(1):5.CrossRefPubMedPubMedCentral
9.
go back to reference Zhang S, Ma C. How has the COVID-19 pandemic affected the utilisation of online consultation and face-to-face medical treatment? An interrupted time-series study in Beijing, China. BMJ Open. 2023;13(2):e062272.CrossRefPubMed Zhang S, Ma C. How has the COVID-19 pandemic affected the utilisation of online consultation and face-to-face medical treatment? An interrupted time-series study in Beijing, China. BMJ Open. 2023;13(2):e062272.CrossRefPubMed
10.
go back to reference Zulman DM, Verghese A. Virtual care, telemedicine visits, and real connection in the era of COVID-19: Unforeseen opportunity in the face of adversity. JAMA. 2021;325(5):437–8.CrossRefPubMed Zulman DM, Verghese A. Virtual care, telemedicine visits, and real connection in the era of COVID-19: Unforeseen opportunity in the face of adversity. JAMA. 2021;325(5):437–8.CrossRefPubMed
11.
go back to reference Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, et al. Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism Relat Disord. 2020;78:134–7.CrossRefPubMedPubMedCentral Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, et al. Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism Relat Disord. 2020;78:134–7.CrossRefPubMedPubMedCentral
12.
go back to reference Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1436–47.CrossRefPubMed Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1436–47.CrossRefPubMed
13.
go back to reference Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. Outcome of hospitalized Parkinson’s disease patients with and without COVID-19. Mov Disord Clin Pract. 2021;8(6):859–67.CrossRefPubMedPubMedCentral Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. Outcome of hospitalized Parkinson’s disease patients with and without COVID-19. Mov Disord Clin Pract. 2021;8(6):859–67.CrossRefPubMedPubMedCentral
14.
go back to reference Sorrell L, Leta V, Barnett A, Stevens K, King A, Inches J, et al. Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: a multicentre UK-based study. PLoS ONE. 2023;18(7):e0285349.CrossRefPubMedPubMedCentral Sorrell L, Leta V, Barnett A, Stevens K, King A, Inches J, et al. Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: a multicentre UK-based study. PLoS ONE. 2023;18(7):e0285349.CrossRefPubMedPubMedCentral
15.
go back to reference Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.ADSCrossRefPubMedPubMedCentral Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.ADSCrossRefPubMedPubMedCentral
16.
go back to reference Zheng KS, Dorfman BJ, Christos PJ, Khadem NR, Henchcliffe C, Piboolnurak P, et al. Clinical characteristics of exacerbations in Parkinson disease. Neurologist. 2012;18(3):120–4.CrossRefPubMedPubMedCentral Zheng KS, Dorfman BJ, Christos PJ, Khadem NR, Henchcliffe C, Piboolnurak P, et al. Clinical characteristics of exacerbations in Parkinson disease. Neurologist. 2012;18(3):120–4.CrossRefPubMedPubMedCentral
17.
go back to reference Anghelescu A, Onose G, Popescu C, Băilă M, Stoica SI, Postoiu R, et al. Parkinson’s disease and SARS-CoV-2 infection: particularities of molecular and cellular mechanisms regarding pathogenesis and treatment. Biomedicines. 2022;10(5):1000.CrossRefPubMedPubMedCentral Anghelescu A, Onose G, Popescu C, Băilă M, Stoica SI, Postoiu R, et al. Parkinson’s disease and SARS-CoV-2 infection: particularities of molecular and cellular mechanisms regarding pathogenesis and treatment. Biomedicines. 2022;10(5):1000.CrossRefPubMedPubMedCentral
20.
go back to reference Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Parkinsons Dis. 2020;10(2):351–4.CrossRefPubMedPubMedCentral Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Parkinsons Dis. 2020;10(2):351–4.CrossRefPubMedPubMedCentral
21.
go back to reference Xia Y, Kou L, Zhang G, Han C, Hu J, Wan F, et al. Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Med. 2020;75:428–33.CrossRefPubMedPubMedCentral Xia Y, Kou L, Zhang G, Han C, Hu J, Wan F, et al. Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Med. 2020;75:428–33.CrossRefPubMedPubMedCentral
23.
go back to reference Qin X, Hsieh CR. Understanding and addressing the treatment gap in mental healthcare: economic perspectives and evidence from China. Inquiry. 2020;57:46958020950566.PubMed Qin X, Hsieh CR. Understanding and addressing the treatment gap in mental healthcare: economic perspectives and evidence from China. Inquiry. 2020;57:46958020950566.PubMed
24.
25.
go back to reference Srivastav AK, Samuel AJ. E-Rehabilitation: One solution for patients with Parkinson’s disease in COVID-19 era. Parkinsonism Relat Disord. 2020;75:128–9.CrossRefPubMedPubMedCentral Srivastav AK, Samuel AJ. E-Rehabilitation: One solution for patients with Parkinson’s disease in COVID-19 era. Parkinsonism Relat Disord. 2020;75:128–9.CrossRefPubMedPubMedCentral
26.
go back to reference Cubo E, Hassan A, Bloem BR, Mari Z. Implementation of telemedicine for urgent and ongoing healthcare for patients with Parkinson’s disease during the COVID-19 pandemic: new expectations for the future. J Parkinsons Dis. 2020;10(3):911–3.CrossRefPubMed Cubo E, Hassan A, Bloem BR, Mari Z. Implementation of telemedicine for urgent and ongoing healthcare for patients with Parkinson’s disease during the COVID-19 pandemic: new expectations for the future. J Parkinsons Dis. 2020;10(3):911–3.CrossRefPubMed
27.
go back to reference Ruggiero F, Lombi L, Molisso MT, Fiore G, Zirone E, Ferrucci R, et al. The impact of telemedicine on Parkinson’s care during the COVID-19 pandemic: an Italian online survey. Healthcare (Basel). 2022;10(6):1065.CrossRefPubMed Ruggiero F, Lombi L, Molisso MT, Fiore G, Zirone E, Ferrucci R, et al. The impact of telemedicine on Parkinson’s care during the COVID-19 pandemic: an Italian online survey. Healthcare (Basel). 2022;10(6):1065.CrossRefPubMed
Metadata
Title
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey
Authors
Pei Huang
Yu-Yan Tan
Biao Chen
Hui-Fang Shang
Li-Juan Wang
Chun-Feng Liu
Ling Chen
Ying Chang
Han Wang
Xue-Lian Wang
Xiao-Guang Lei
Li-Fen Yao
Yang Yu
Zheng Ye
Hai-Bo Chen
Sheng-Di Chen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2024
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-024-00399-9

Other articles of this Issue 1/2024

Translational Neurodegeneration 1/2024 Go to the issue